Research

New Research Quantifies the GLP-1 + Aesthetics Overlap: Treating the Face After Weight Loss

“Ozempic face” is no longer just a social-media phrase — it is now a clinical conversation with data behind it. New January research and physician surveys show how weight-loss medicine is reshaping who walks into an aesthetic practice, and why.

injector.world Editorial Team
Editorial Team
Published January 20, 2026
Quick answer

New research published in January 2026 in Aesthetic Surgery Journal Open Forum examines how clinicians approach nonsurgical facial and neck treatment in patients who have lost significant weight on GLP-1 medications. Accompanying physician-survey data reported that roughly one-third of physicians say GLP-1 use has increased dermal filler volume in their practice.

At a glance
  • Study: "Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1
  • Receptor Agonist Weight Loss Patients," Aesthetic Surgery Journal Open Forum,
  • published January 2026.
  • Survey signal: ~33% of physicians report GLP-1 use increased filler volume.
  • Common approaches discussed: volume-restoring fillers, biostimulators.
  • Theme: weight-management and aesthetic care are increasingly intertwined.

Rapid weight loss can change the face. As fat volume decreases, some patients notice hollowing, laxity, and a more aged or gaunt appearance — a phenomenon popularly nicknamed "Ozempic face." The clinical question is what to do about it, and a January 2026 paper in Aesthetic Surgery Journal Open Forum, titled "Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients," offers experience-based considerations for treating this growing group.

Alongside the publication, market research highlighted by Allergan Aesthetics — which has studied the intersection of medical weight loss and aesthetics since early 2022 — reported that about one-third of physicians (33%) say GLP-1 use has increased the overall volume of dermal filler injections in their practice. The through-line is that patients succeeding on weight medications are increasingly seeking physician-guided aesthetic options to rebalance facial appearance, often favoring volume-restoring fillers and collagen-stimulating biostimulators.

WHY IT MATTERS

This is the clearest evidence yet of the "convergent patient" — one person moving across categories that used to be marketed and discovered separately. For consumers, it underscores the value of a provider who understands both the metabolic and aesthetic sides of the picture, rather than treating each in isolation. It also reframes facial changes after weight loss as an expected, manageable consideration to discuss in advance — not an unavoidable surprise.

Frequently asked questions

What is "Ozempic face"?
An informal term for facial volume loss, hollowing, or laxity that can follow significant or rapid weight loss, including on GLP-1 medications.
Are fillers the only option after weight loss?
No. Options discussed in the literature include hyaluronic acid fillers and biostimulators, among others; the appropriate plan is individualized with a qualified provider.
Sources (2)
  1. 1.MWL data and changing patient profile (references the Jan 2026 ASJ Open Forum publication)Allergan Aesthetics / AbbVie
  2. 2.Aesthetic Surgery Journal Open Forum (Oxford Academic)Aesthetic Surgery Journal Open Forum (Oxford Academic)

About this article

Written by the injector.world editorial team
Factual, independent reporting. No sponsored content.
Our editorial standards
This is editorial reporting. It is not medical advice. Consult a qualified provider before starting any treatment.
Stay in the loop

Get the latest news in your inbox.

You will receive a confirmation email. Unsubscribe anytime.